CheckEye’s Post

🚨 Breakthrough in Diabetes Treatment! 🚨 Exciting news from the world of medical research! Chinese scientists have reportedly achieved a significant milestone by curing a type-1 diabetes patient through cell transplants. A 25-year-old woman, who had been living with this condition for over a decade, no longer requires insulin injections following a minimally invasive surgery. This groundbreaking work, published in the journal Cell, has the potential to pave the way for new and innovative treatments for diabetes. This development not only highlights the incredible advancements in medical science but also brings hope to millions affected by type-1 diabetes. Kudos to the researchers for their dedication and innovation! #DiabetesResearch #MedicalBreakthrough #HealthcareInnovation #Type1Diabetes #CellTransplant #MedicalScience

Are you interested in learning more about the surgical treatment of headache disorders? Check out our latest publication in #CurrentNeurologyandNeuroscienceReports. We outline the most recent advancements, from the use of #MRNeurography and #MachineLearning to improve patient screening, to the newest surgical techniques to treat nerve compression and neuromas in the head and neck. Read the full article here: https://lnkd.in/e4X4WsYW With Lisa Gfrerer MD PhD Leonard Knödler Katya Remy Austen Jr.

InsulinAPP and Clinical Outcomes! Exciting new research reveals that the Electronic Glycemic Management System (InsulinAPP) significantly improves glycemic control and reduces complications in diabetes patients undergoing coronary artery bypass surgery. This randomized controlled trial demonstrated that patients managed with InsulinAPP had lower mean glucose levels, fewer hospital-acquired infections, and shorter hospital stays compared to those receiving conventional care. Lead author Alexandre Barbosa Câmara de Souza, PhD, and team highlight the potential of digital health protocols in optimizing inpatient diabetes management. Read more about our innovative approach and promising outcomes in our latest publication! https://lnkd.in/dGryyy_z hashtag #DiabetesCare hashtag #DigitalHealth hashtag #ClinicalResearch hashtag #InsulinAPP For non-critical patients: www.insulinapp.com.br For critical patients: www.insulinapp-uti.com.br

𝐋𝐚𝐭𝐞𝐬𝐭 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐢𝐧 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 (𝐍𝐄𝐉𝐌) 𝐋𝐨𝐧𝐠 𝐂𝐎𝐕𝐈𝐃 𝐀𝐜𝐫𝐨𝐬𝐬 𝐕𝐚𝐫𝐢𝐚𝐧𝐭𝐬 A study of over 440,000 veterans reveals how Postacute Sequelae of SARS-CoV-2 (PASC) differ between the Pre-Delta, Delta, and Omicron eras. Understanding the long-term effects is key to public health. 𝐈𝐕 𝐀𝐦𝐢𝐧𝐨 𝐀𝐜𝐢𝐝𝐬 𝐟𝐨𝐫 𝐊𝐢𝐝𝐧𝐞𝐲 𝐏𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 For patients undergoing cardiac surgery, intravenous amino acids could be the next step in reducing kidney damage and improving recovery outcomes. 𝐀𝐧𝐝𝐞𝐱𝐚𝐧𝐞𝐭 𝐟𝐨𝐫 𝐁𝐫𝐚𝐢𝐧 𝐇𝐞𝐦𝐨𝐫𝐫𝐡𝐚𝐠𝐞𝐬 A breakthrough treatment for Factor Xa inhibitor-associated intracerebral hemorrhage shows promise but comes with higher thrombotic risk. Balancing benefits and risks is critical. 𝐒𝐭𝐚𝐲 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐨𝐧 𝐭𝐡𝐞𝐬𝐞 𝐢𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 Source- https://lnkd.in/gXbW4Sa3 #MedicalInnovation #NEJMResearch #COVID19 #KidneyCare #NeurologyBreakthroughs

🎉 🎉 🎉 During the #CREATE Symposium, Dr.Kevin Ka-ho KAM, Director of Ambulatory Cardiology Services at the Department of Medicine & Therapeutics, Prince of Wales Hospital & Honorary Associate Professor of CUHK Medicine,香港中文大学, delivered a speech titled "Re-defining Standard of Practice: Heart Failure and Fluid Assessment Using New Device ". 👉He provided an in-depth introduction to a Re-Defining Standard of care – Heart failure and Fluid assessment (ReDS-HF) project, which can identify patients with residual pulmonary congestion for early intervention and reduce heart failure hospitalizations. ✨ Follow us and stay tuned for the upcoming videos! More speech videos from our guest speakers are coming soon! Know more about #CAIR: https://lnkd.in/gBjV7zPW #AI #embodiedai #surgery #healthcare #MedTech #CUHK #PWH #Heartfailure #Fluidassessment #Cardiology

🤔 How CheckEye’s data supports scientific breakthroughs A recent article in the journal Biomedicines MDPI explored the link between microvascular changes in the retina and the progression of diabetic retinopathy. 📖 The research was based on findings from our study, published in 2024 in the Journal of Ophthalmology (Ukraine). 🔬 Key takeaways from the research: - Microvascular changes in the retina are key indicators of diabetic retinopathy progression. - Artificial intelligence proved highly effective in analyzing retinal images and assessing disease stages. - Our platform’s data helped validate the diagnostic methods described in this new study. We’re pleased to see how our research contributes to advancing science and supports impactful discoveries in healthcare. 🙏 A special thanks to Cristina Cuscó Marigó, PhD and co-authors for their fascinating article and for utilizing CheckEye’s data in their analysis! 📌 Read more about the study: https://lnkd.in/dghun47e #AI #DiabeticRetinopathy #HealthTech #Science #CheckEye

Every FOP NM we place matters! Why? Just like every drop matters in the ocean, every FOP NM deployed by Team Remidio matters as it brings more patients closer to screening and helps us make a difference in the lives of millions, one eye at a time! As we gear up to deploy our 1,000th FOP NM in the US into the hands of care providers, we are excited to share this milestone with you, as we are clearly enthusiastic about revolutionizing the future of eye care. Why again? Remidio's Chief Commercial Officer, Erik Hafkey, shares our vision - "Our goal is to impact the lives of nearly 30M at risk for Diabetic Retinopathy in the US. New partnerships with proven technologies will be required to reach this goal.” Read more and get to know us better by clicking the link. #remidio #ai #medical #research #ophthalmology #science #visualhealth #ophthalmicintelligence #innovation #artificialintelligence #medtech #eye #AI #diabeticretinopathy #ophthalmologist

We are proud to announce that CureSight™ was found to be SUPERIOR over patching! A recent study published in the prestigious American Journal of Ophthalmology (AJO) titled “High-adherence dichoptic treatment versus patching in anisometropic and small angle strabismus amblyopia: a randomized controlled trial” showed that patients using CureSight, our innovative digital binocular amblyopia treatment device, achieved significantly greater visual acuity gains in per-protocol analysis compared to those undergoing traditional patching! The study included 149 children with amblyopia (also known as “lazy eye”) who were randomized to either CureSight digitized binocular treatment or patching, and was conducted by the Pivotal Trial Group in multiple centers in the US and Israel. Key findings include: ⭐ Per protocol (PP) analysis: results from the per protocol (PP) dataset of the trial demonstrated that CureSight was significantly more effective than patching with greater VA improvements and higher adherence rates compared to those undergoing patching. The CureSight group (n=54) experienced a mean improvement of 2.8 lines in distance VA after 16 weeks of treatment—0.53 lines higher than the patching group (n=56). ⭐ Modified intent-to-treat (mITT) analysis: The mITT CureSight group demonstrated a median adherence rate of 94%, significantly higher than the 83.9% adherence rate observed in the patching group. Dr. Nicholas Sala, DO, of Pediatric Ophthalmology of Erie stated that “The entire body of CureSight clinical trial evidence—and the most recent findings in particular—demonstrate that this treatment can greatly benefit our patients. As a clinical investigator in a CureSight clinical trial, I had the opportunity to offer this treatment to my patients and found it to be easy to use, effective, and appealing to children.” Read the full study here: https://lnkd.in/dmUUcmTm We are deeply grateful to the authors for their dedication and contributions to this significant achievement: Tamara Wygnanski-Jaffe burton kushner The CureSight Pivotal Trial Group Avital Moshkovitz, Ph.D Michael Belkin Oren Yehezkel Congratulations to the entire team on reaching this important milestone! #superiority #digitalhealth #visioncare #medicaldevice #amblyopia #binocular #ophthalmology

🌟 Light Therapy Breakthrough: The Solution for High Myopia in Children and Adolescents 🌟 👓 Are you concerned about your child's myopia? High myopia has become a significant challenge in ophthalmology worldwide, potentially leading to serious complications such as myopic macular degeneration and glaucoma. Fortunately, repetitive low-intensity red light (RLRL) therapy offers new hope. 🔬 A recent study investigated the effects of low-intensity red light (650 nm) therapy on 192 myopic children aged 6 to 16 years. The treatment involved 3 minutes of therapy twice a day for one week. The results were promising: RLRL effectively slowed the lengthening of the eye axis and promoted scleral repair, with 53.3% of participants experiencing a significant shortening of the eye axis. This is currently the only proven method to achieve such results. 🔍 This groundbreaking discovery provides a safe and effective non-invasive treatment option for controlling the progression of high myopia, offering hope for a clearer future for many young patients. Source: https://bit.ly/3O5sTJC #MyopiaManagement #ChildEyeHealth #RedLightTherapy #HighMyopia #Ophthalmology #VisionCare #EyeHealth #NonInvasiveTreatment #ScleralRepair #PreventMyopia

In December 2024, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned cervical ripening during labor induction in different settings, fasciectomy surgery for Dupuytren's contracture in adults, hybrid closed-loop systems in type 1 diabetes, point-of-care tests for urinary tract infections. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs NICE guidance: https://lnkd.in/eNqVfmNE